Unilever CEO Hein Schumacher to step down
Investing.com -- Unilever PLC (LON:ULVR) said on Tuesday that its Chief Executive Officer Hein Schumacher, is set to leave the company, in a surprise move.
The consumer goods giant said that Schumacher's departure will take effect on May 31 and that Fernando Fernandez, the current Chief Financial Officer, has been named his successor.
Schumacher's tenure at Unilever has been relatively brief, having taken over as CEO from Alan Jope in July 2023. Despite Schumacher's departure, Unilever has stated that its guidance for 2025 remains unchanged.
Fernandez brings considerable experience to his new role. Prior to serving as the company's Chief Financial Officer, he was the president of Unilever's beauty and wellbeing unit.
'The Board has been impressed with Fernando's decisive and results-oriented approach and his ability to drive change at speed. He partnered in the development of the GAP and in driving the productivity programme." Unilever Chairman Ian Meakins said in a press release.
"He has a strong track record of performance and portfolio management, a love of brands and a profound knowledge of Unilever's operations," he added.
The company also added that Fernando will receive fixed pay of Euro 1,800,000 and will be eligible to participate in an annual bonus and Performance Share Plan awards, in line with Unilever's policy.
An internal and external search process has been initiated to appoint a permanent CFO, while Srinivas Phatak, currently Unilever's Deputy CFO will serve as acting CFO.
Related Articles
Unilever CEO Hein Schumacher to step down
Tesla updates autopilot software in China, owners say move falls short of hopes
India's Reliance touts 'brain mapping' to lure IPL advertisers after Disney merger
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation Strategy AUSTIN, Texas, June 9, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company"), today issued the following statement regarding the results of the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"): "We believe the outcome of the Annual Meeting underscores what we have consistently conveyed to Keros' Board of Directors: there is broad and growing concern among stockholders regarding the Board's capital allocation decisions and fidelity to stockholder interests. ADAR1 previously disclosed its intention to withhold votes from Dr. Mary Ann Gray and Dr. Alpna Seth at the Annual Meeting. These two directors received among the highest level of shareholder opposition of any directors standing for election in 2025. In our view, this result reflects a substantial loss of stockholder confidence in the Board and clear dissatisfaction with the status quo. With only approximately 34% of outstanding shares voting to elect Dr. Gray and only 37% voting to elect Dr. Seth, the Board must recognize the widespread dissatisfaction with its stewardship of the Company. We appreciate the Company's recent decision to discontinue development of cibotercept in pulmonary arterial hypertension and, finally, implement a reduction in headcount. While these delayed actions are directionally positive, they are wholly insufficient and, in our view, are overshadowed by the Board's baffling decision to return only a modest portion of the Company's excess capital to stockholders. We can think of no credible justification for the Company to retain approximately half of its cash balance given its limited clinical pipeline and commercial prospects. In fact, at an investor conference today, CEO Jasbir Seehra acknowledged that the capital being held exceeds what is needed to fund the Company's current DMD program and may instead be used to pursue other high risk, hyper-competitive indications. Even more troubling is the lack of detail around the proposed capital return ― including the Board's failure to specify the terms, timing and method ― despite its claims to have completed a "thorough" and "comprehensive" review of strategic alternatives. In our view, this reflects a haphazard and incoherent approach to decision-making. In order for the Board to follow through on its stated commitment to maximizing value, it must take immediate and concrete action to reduce costs more aggressively, commit to returning $475 million (i.e., an additional $100 million over the currently proposed amount) to stockholders through a special dividend by the end of Q3 2025, and ensure that stockholders can directly capture the potential cash flow from the Takeda partnership through a contingent value right or similar mechanism, which should be implemented no later than year-end. ADAR1 continues to believe Keros possesses significant upside potential. But realizing that potential will require fresh perspectives in the boardroom and a disciplined, investor-focused approach to capital stewardship. Shareholders have spoken and the current directors do not have the support of a majority of shareholders. If the Board nevertheless insists on clinging to a failed strategy, ADAR1 will not hesitate to hold it accountable, including by nominating new directors for election at the 2026 Annual Meeting. We are committed to ensuring that the will of investors is not ignored, and we will continue engaging with the Company and our fellow investors to see that the desires of stockholders are heard and respected." About ADAR1 Capital ManagementADAR1 Capital Management is an SEC-registered investment manager based in Austin, Texas, focused on public and private equity investments in the life sciences and biotechnology sectors. The firm was founded in October 2018 by Dr. Daniel Schneeberger, who brings over 20 years of experience spanning scientific research, healthcare consulting, institutional investing, and executive leadership in the healthcare industry. He is supported by a team of experienced professionals with deep medical and scientific expertise and a strong track record of biopharmaceutical investing. Contact:info@ View original content: SOURCE ADAR1 Capital Management, LLC
Yahoo
5 hours ago
- Yahoo
Cricket-T20 can be US craze like yoga and Bollywood weddings
By Amlan Chakraborty (Reuters) -Indian-American businessman Sanjay Govil is convinced Twenty20 cricket can be the next big cultural import into the United States, following a trail blazed by yoga and Bollywood-style weddings. Previous investors have held similar dreams of breaking into the U.S. sports league market, only to be thwarted by the nation's obsession with baseball, basketball and American football. IT entrepreneur Govil, however, is confident that along with Microsoft's India-born CEO Satya Nadella and Silicon Valley's Anand Rajaraman and Venky Harinarayan he can embed the short, jazzy version of cricket deeply into the U.S. sporting landscape "T20 leagues are the future," Govil, who owns Washington Freedom, one of the six franchises in the Major League Cricket (MLC), told Reuters. "Like Yoga, like Bollywood weddings, things from India and it's crazy here. "People here just love Indian wedding. When we have weddings in hotels, people just stop and watch. It's a spectacle, right?" Although cricket originated in England, India is now its financial engine with a cash cow in named the Indian Premier League (IPL) T20 competition, which has a brand value of $12 billion. IPL franchises with deep pockets also own teams in leagues in England, South Africa, United Arab Emirates, West Indies and the United States. The U.S. featured in the first international cricket match, against Canada, in New York in 1844, but cricket remains very much a niche sport in the country. RAISED PROFILE The introduction of the MLC in 2023 and staging matches in last year's T20 World Cup have raised the game's profile. Cricket returning to Olympics after a gap of 128 years at the 2028 Los Angeles Games will be "another big impetus", said Govil, who was born in Canada but grew up in New Delhi before moving to the U.S. Govil, who also owns 50% stake in the Welsh Fire franchise of The Hundred tournament in England, said MLC franchises learned a lot from their interaction with IPL counterparts. "One of the IPL owners came to my house and he educated me on how to build a team," he said. The presence of India's marquee players in the MLC would have been the icing on the cake but Govil respects the Indian board's policy of not allowing its players to take part in leagues abroad. "I'm sure they have some logic behind why they're doing what they're doing, and I respect that," he said. "I have to succeed in the cards which are dealt to me." Govil knows that cricket in the U.S. cannot rely only on the Indian market or south Asian diasporas in order to be successful. "We want to grow domestic talent. We cannot just rely on international players," he said. "We also have to create our own market here, because we cannot just rely on Indian eyeballs watching our matches." "We are in this for a long haul," Govil added. "We are making a lot of investments. We all have to have our own stadiums. "Once we have like eight or nine stadiums, that's when you're going to really see cricket growing in the U.S." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom
Deep Track's Nominees Are Prepared to Collectively Enter the Boardroom with Open-Minded Perspectives, Constructive Approach and Sole Focus on Creating Value for All Shareholders Believes that Without Meaningful Board Change "Valid and Critical Questions Regarding Dynavax's Strategic Direction, Capital Allocation, and Board Responsiveness" Will Remain Unanswered Details Urgent Need to Address Company's Consistent Failure to Achieve Stated Targets and Reverse Heplisav Market Share Stagnation GREENWICH, Conn., June 09, 2025--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.82% of the Company's outstanding shares, today issued a letter to shareholders detailing the benefits of electing Deep Track's four nominees – Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel – to the Board of Directors (the "Board") at the upcoming 2025 Annual Meeting of Shareholders (the "Annual Meeting") on June 11, 2025. For more information, including details on how to vote Deep Track's WHITE proxy card, please visit The full text of the letter follows: Dear Fellow Dynavax shareholders, We would like to express our appreciation for the opportunity we have had over the course of this campaign to engage with so many of you. Deep Track undertook this effort because, as one of Dynavax's largest and longest-tenured shareholders, we believe deeply in the Company and its value creation potential. With the Annual Meeting now only a few days away, we want to convey a few final thoughts about why we believe new, independent and fully objective perspectives should be added to the Board. First, the numbers speak for themselves. The key asset at Dynavax is Heplisav, but under the Board's increasing pressure for inorganic growth, Heplisav is not reaching its full potential. As outlined in the Company's proxy statement1, Heplisav failed to achieve both key metrics established by the Board: 2024 Board Target 2024 Result Outcome Heplisav U.S. sales $275 million $268 million Missed by $7 million U.S. market share in 4Q 47% 44% Missed by 3 p.p. Management cautions that market share numbers should only be evaluated on a year-over-year basis and dismisses the slip to 43% market share in the first quarter of 2025. But even through that lens the numbers are troubling: fourth quarter market share in 2023 was 42%2, which means there were only two percentage points of growth in 2024 – a substantial decline from the seven points achieved in the year prior. At this rate, Heplisav will fall far short of the Company's 60% target for 2030 – yet management contended on the earnings call last month that this is "exactly how we had planned."3 Shares fell 11% the next day.4 We believe that growing questions about Heplisav growth with a distracted management team combined with an outsized cash pile with no coherent strategy for deployment have taken their toll on the share price. While the Company points to a "pivot" in 2019 when it made the unsurprising choice to focus on its only approved product, this reference point ignores the multi-year losses since then – both on an absolute basis and against the Company's benchmark historically used in its own proxy filings5, the Nasdaq Biotechnology Index (NBI): DVAX NBI DVAX vs. NBI One year -17% -6% -10% Two years -12% +2% -14% Three years -15% +17% -32% Slowing market share growth, missed revenue targets, and a stock price meaningfully underperforming the Company's index for years all point to fundamental problems at Dynavax – problems that are a direct result of the questionable Board strategy of diversifying the Company away from its lead asset. Second, without new voices in the boardroom, nothing will change. As leading proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") noted in its report,6 our campaign "…highlighted valid and critical questions regarding Dynavax's strategic direction, capital allocation, and board responsiveness." By voting for the incumbent directors up for election, you would be voting to leave these questions unaddressed and effectively assenting to the current strategy set by Chairman Scott Myers without any further debate, assessment, or new thinking. As Glass Lewis wrote when recommending against Mr. Myers, shareholders would be "best served" by electing Deep Track directors who would bring "relevant and differentiated perspectives to the Board." Shareholders must also keep in mind that a "wait and see" approach simply will not work. Due to the Board's imbalanced class of directors and the classified structure not ending until 2028, there is only one independent director up for election next year – making this year's Annual Meeting a uniquely important opportunity to effect real change.7 Finally, the truth about Deep Track and our nominees. The current Board has made repeated and increasingly baseless mischaracterizations regarding Deep Track, our nominees and our campaign. Consider these facts: Our director nominees are open-minded and ready to work constructively to do what is best for all Dynavax shareholders. Suggesting that highly respected and experienced professionals like our nominees would violate their fiduciary duties is nothing more than campaign theatre. The Company has particularly targeted Deep Track principal Brett Erkman, accusing him of being "rigid" in his views. In fact, all evidence points to the contrary: in the years of engagement Brett has had with Dynavax and the communications over the course of this campaign (including the very last settlement offer he proposed to Ryan Spencer on April 17, 2025, which the Board flatly rejected over a week later with no substantive dialogue in the interim), Brett consistently and explicitly made clear that he was always "open to discussion" and "happy to engage" on any point of potentially differing opinions, including specifics on capital allocation, board composition and the components of the two-year standstill. Deep Track is one of Dynavax's largest and longest-tenured investors – the antithesis of "short-term." Our principals first invested in Dynavax a decade before any incumbent director up for election this year had joined the Board. The idea that we are looking for a quick profit at the expense of the Company's best interests is simply false. We also do not understand how the Board can believe a single shareholder representative could engineer such an outcome; again, this is more theatre that defies logic and yet another attempt to distract from the facts. Deep Track is not a typical "activist" – this is the first time we have publicly engaged at all with a portfolio company, much less run a proxy contest. Our nominees would bring needed valuable experience, independence and investor perspective to the Dynavax Board. Throughout this campaign, we have struggled to understand why Dynavax has fought so hard (while spending shareholder capital) to prevent a nearly 15% shareholder from having a representative on the Board. Regardless of these motivations, the reality is that our directors are needed. As Glass Lewis concluded in its report, "...we find that the board is notably lacking in directors with direct capital markets or institutional investor backgrounds," and specifically regarding Brett, "Mr. Erkman's extensive background as a public equity investor in the life sciences sector addresses what we believe is a notable deficiency in the current board's composition and could help sharpen the board's approach to capital allocation, shareholder engagement, and long-term value creation." We appreciate you taking the time to consider our views. We truly believe that by voting for all four Deep Track nominees, you can help to unlock the value that Dynavax can deliver and put the Company on a better path to success. For more information, including details on how to vote Deep Track's WHITE proxy card, please visit Regards, David KroinFounder and Chief Investment Officer, Deep Track Capital LP EVERY VOTE MATTERS Your vote is important, no matter how many shares of Common Stock you own. If you have any questions, require assistance in voting your WHITE proxy card, or need additional copies of Deep Track's proxy materials, please visit or contact our proxy solicitor, Innisfree M&A Incorporated ("Innisfree"), using the contact information provided here: Innisfree M&A Incorporated501 Madison Avenue, 20th FloorNew York, New York 10022Stockholders call toll-free (877) 687-1865 About Deep Track Capital Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. We develop long term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies. In addition to capital, we seek to invest our time and expertise, while leveraging our network for the benefit of our partners. We aim to lead transactions while building large syndicates, and also to invest in rounds led by other qualified investors. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS The information herein contains "forward-looking statements." Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "potential," "targets," "forecasts," "seeks," "could," "should" or the negative of such terms or other variations on such terms or comparable terminology. Similarly, statements that describe our objectives, plans or goals are forward-looking. Forward-looking statements are subject to various risks and uncertainties and assumptions. There can be no assurance that any idea or assumption herein is, or will be proven, correct. If one or more of the risks or uncertainties materialize, or if any of the underlying assumptions of Deep Track Capital, LP ("Deep Track") or any of the other participants in the proxy solicitation described herein prove to be incorrect, the actual results may vary materially from outcomes indicated by these statements. Accordingly, forward looking statements should not be regarded as a representation by Deep Track that the future plans, estimates or expectations contemplated will ever be achieved. Certain statements and information included herein may have been sourced from third parties. Deep Track does not make any representations regarding the accuracy, completeness or timeliness of such third party statements or information. Except as may be expressly set forth herein, permission to cite such statements or information has neither been sought nor obtained from such third parties. Any such statements or information should not be viewed as an indication of support from such third parties for the views expressed herein. Deep Track disclaims any obligation to update the information herein or to disclose the results of any revisions that may be made to any projected results or forward-looking statements herein to reflect events or circumstances after the date of such information, projected results or statements or to reflect the occurrence of anticipated or unanticipated events. CERTAIN INFORMATION CONCERNING THE PARTICIPANTS Deep Track and the other Participants (as defined below) have filed a definitive proxy statement and accompanying WHITE universal proxy card with the Securities and Exchange Commission (the "SEC") to be used to solicit proxies for, among other matters, the election of its slate of director nominees at the 2025 annual stockholders meeting (the "2025 Annual Meeting") of Dynavax Technologies Corporation, a Delaware corporation ("DVAX"). Shortly after filing its definitive proxy statement with the SEC, Deep Track furnished the definitive proxy statement and accompanying WHITE universal proxy card to some or all of the stockholders entitled to vote at the 2025 Annual Meeting. The participants in the proxy solicitation are Deep Track, Deep Track Biotechnology Master Fund, Ltd. (the "Record Stockholder"), David Kroin (all of the foregoing persons, collectively, the "Deep Track Parties"), Brett A. Erkman, Jeffrey S. Farrow, Michael Mullette and Donald J. Santel (such individuals, collectively with the Deep Track Parties, the "Participants"). As of the date hereof, the Deep Track Parties beneficially own an aggregate of 17,791,486 shares (the "Deep Track Shares") of the common stock, par value $0.001 per share, of DVAX (the "Common Stock"). The Deep Track Shares collectively represent approximately 14.53% of the outstanding shares of Common Stock based on 122,411,685 shares of Common Stock outstanding as of the record date for the 2025 Annual Meeting as reported in DVAX's Definitive Proxy Statement filed with the SEC on April 17, 2025. Each of the Deep Track Parties may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Deep Track Shares. As of the date hereof, none of the other Participants beneficially own any shares of Common Stock. IMPORTANT INFORMATION AND WHERE TO FIND IT DEEP TRACK STRONGLY ADVISES ALL STOCKHOLDERS OF DVAX TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS TO SUCH PROXY STATEMENT, AND OTHER PROXY MATERIALS FILED BY DEEP TRACK WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEBSITE AT THE DEFINITIVE PROXY STATEMENT, WHEN FILED, AND OTHER RELEVANT DOCUMENTS, WILL ALSO BE AVAILABLE BY DIRECTING A REQUEST TO THE PARTICIPANTS' PROXY SOLICITOR, INNISFREE M&A INCORPORATED, 501 MADISON AVENUE, 20th FLOOR, NEW YORK, NY 10022 (STOCKHOLDERS CAN CALL TOLL-FREE: (877)-687-1865). __________________________ 1 Dynavax definitive proxy statement filed April 17, 2025. 2 Dynavax 4Q23 earnings call, recorded Feb 22, 2024. 3 Dynavax 1Q25 earnings call recorded May 6, 2025. 4 Share price calculated market close May 6, 2025 through market close May 7, 2025. 5 Dynavax definitive proxy statement filed April 11, 2024. 6 Permission to quote Glass Lewis was neither sought nor received. 7 Dynavax 2025 proxy statement filed April 17, 2025, identifies Daniel L. Kisner (independent) and Ryan Spencer (CEO) as the only Class II directors continuing in office until the 2026 annual meeting. View source version on Contacts Investor Contact Innisfree M&A IncorporatedScott Winter / Gabrielle Wolf+1 212-750-5833 Media Contact Longacre Square Partnersdeeptrack@
